European Journal of Dermatology
MENUBrodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal Volume 30, issue 6, November-December 2020
Figures
1 Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, France
2 CIRI (International Center for Infectiology Research), INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5308, 21 Avenue Tony Garnier, 69007 Lyon, France
a These authors contributed equally
- DOI : 10.1684/ejd.2020.3910
- Page(s) : 741-3
- Published in: 2020
The interleukin (IL)-17 cytokine family plays a key role in the pathogenesis of psoriasis [1]. Several monoclonal antibodies targeting IL-17A (ixekizumab, secukinumab) or the IL-17 receptor A (IL-17 RA; brodalumab) have recently been approved for the treatment of patients with moderate-to-severe plaque psoriasis [2]. These are all highly effective and well tolerated. Recent reports have highlighted the occurrence of eczematous eruptions in 2 to 5% of patients under IL-17A-F inhibitors[3, 4]. [...]